Payment overview · 2025
General Payments
$116,402.57
356 reported records · 33 companies
Healthcare provider profile · identity verified
Mark A Landrio, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WINCHESTER, VA · NPI 1063441533
Verified facts
What the public records show
CMS Open Payments records show Mark A Landrio, M.D. received $116,402.57 in general payments during 2025 across 356 reported records.
EMD Serono, Inc. accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gamunex-C, Panzyga, Tysabri, Ultomiris, Vyvgart Hytrulo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Botox by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART HYTRULO as an associated drug or biological on 16156 records involving 4992 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vyvgart Hytrulo by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ultomiris by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tysabri by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Privigen by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Panzyga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $53,503.34 | 46.0% | 54 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $20,013.37 | 17.2% | 24 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18,117.85 | 15.6% | 31 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $11,059.87 | 9.5% | 20 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $8,649.81 | 7.4% | 45 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $2,220.18 | 1.9% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $277.54 | 0.2% | 27 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $252.92 | 0.2% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $195.43 | 0.2% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $180.93 | 0.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $165.07 | 0.1% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.55 | 0.1% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $152.09 | 0.1% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $149.04 | 0.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.52 | 0.1% | 9 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $141.62 | 0.1% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $141.59 | 0.1% | 26 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $132.96 | 0.1% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $109.92 | 0.1% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $97.22 | 0.1% | 4 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $84.46 | 0.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $76.58 | 0.1% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $75.12 | 0.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $45.91 | 0.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $45.73 | 0.0% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $42.00 | 0.0% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $33.95 | 0.0% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.05 | 0.0% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.67 | 0.0% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.30 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.12 | 0.0% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $20.98 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.88 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,894.00 | 25 |
| Travel and Lodging | $18,939.67 | 44 |
| Consulting Fee | $11,536.00 | 7 |
| Food and Beverage | $6,932.91 | 279 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $52,398.81 | 30 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $18,963.37 | 23 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18,117.85 | 31 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $11,059.87 | 20 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $7,826.45 | 31 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $2,220.18 | 14 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $1,050.00 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $876.63 | 12 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $335.49 | 20 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $227.54 | 24 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $195.43 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $177.44 | 10 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $164.55 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $152.09 | 10 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $141.62 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $141.59 | 26 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $128.56 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $118.18 | 12 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $109.92 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $97.22 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.11 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.11 | 6 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $88.92 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $88.92 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $76.58 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $75.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.12 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $45.73 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $26.03 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $17.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART HYTRULO vyvgart hytrulo |
2025 | Vyvgart Hytrulo | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART HYTRULO open payments reported associated product |
CMS Open Payments — General Payments 16156 supporting records · 4992 recipient NPIs · example record 1240416058 |
Vyvgart Hytrulo · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 174 | 23 |
| Donepezil Hcl | Donepezil Hcl | 86 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 14 |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 35 | suppressed |
| Topiramate | Topiramate | 34 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Gabapentin | Gabapentin | 19 | suppressed |
| Vyvgart Hytrulo | Efgartigimod-Hyaluronidas-Qvfc | 19 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 18 | suppressed |
| Ultomiris | Ravulizumab-Cwvz | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Tysabri | Natalizumab | 15 | suppressed |
| Botox | Onabotulinumtoxina | 14 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116,402.57 · 356 records | EMD Serono, Inc. | ACTHAR, AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, CREXONT, CUTAQUIG, EMGALITY, Gamunex-C, HYQVIA, Hizentra, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Mavenclad, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, Radicava, Rystiggo, SKYCLARYS, Sunosi, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, WatchPATONE, XYWAV, ZAVZPRET, ZEPBOUND, ZEPOSIA, Zilbrysq | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error